Wealthcare Capital Partners LLC Sells 133 Shares of Zoetis Inc. $ZTS

Wealthcare Capital Partners LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 6.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,787 shares of the company’s stock after selling 133 shares during the quarter. Wealthcare Capital Partners LLC’s holdings in Zoetis were worth $279,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Lindbrook Capital LLC grew its stake in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after buying an additional 65 shares during the last quarter. Scott & Selber Inc. grew its stake in shares of Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the last quarter. Secure Asset Management LLC grew its stake in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after buying an additional 68 shares during the last quarter. Quotient Wealth Partners LLC grew its stake in shares of Zoetis by 2.3% during the first quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock worth $521,000 after buying an additional 72 shares during the last quarter. Finally, Broadway Wealth Solutions Inc. grew its stake in shares of Zoetis by 4.4% during the first quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company’s stock worth $287,000 after buying an additional 73 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Saturday, September 27th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and decreased their target price for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Price Performance

ZTS stock opened at $146.45 on Friday. The firm has a market cap of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The company’s fifty day simple moving average is $149.79 and its 200 day simple moving average is $155.08.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.